Skip to main content
. Author manuscript; available in PMC: 2015 Apr 9.
Published in final edited form as: Br J Haematol. 2011 Sep 26;155(5):588–598. doi: 10.1111/j.1365-2141.2011.08888.x

Figure 6. Combination of low doses of SRT1720 and bortezomib or dexamethasone enhances MM cell death.

Figure 6

Low doses of SRT1720 and bortezomib trigger additive anti-MM activity in MM cells. MM.1S (A), MM.1R (B), or RPMI-8226 (C) cells were treated for 24 h with the indicated concentrations of SRT1720, bortezomib, or SRT1720 plus bortezomib; and then assessed for viability using MTT assays (mean ± SD; n = 3). (D) Low doses of SRT1720 and dexamethasone trigger additive anti-MM activity in MM cells. MM.1S cells were treated for 24 h with indicated concentrations of SRT1720, dexamethasone, or SRT1720 plus dexamethasone and then assessed for viability using MTT assays. Shown is mean ± SD of three independent experiments.